Lucid Diagnostics Inc. (NASDAQ:LUCD) Stock Has Average Price Target of $4.19 According to Brokerages

Lucid Diagnostics Inc. (NASDAQ:LUCD) has earned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $4.19.

LUCD has been the subject of a number of analyst reports. Needham & Company LLC reaffirmed a “buy” rating on shares of Lucid Diagnostics in a report on Thursday, October 1st. BTIG Research reissued a “buy” rating on shares of Lucid Diagnostics in a research note on Friday, October 23rd. Finally, Weiss Ratings lowered shares of Lucid Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 18th.

Institutional Investors Weigh In On Lucid Diagnostics

Large investors have recently modified their holdings of the stock. Alyeska Investment Group L.P. acquired a new position in shares of Lucid Diagnostics in the 2nd quarter worth approximately $9,477,000. BlackRock Inc. acquired a new stake in Lucid Diagnostics in the 2nd quarter valued at $8,959,000. Two Seas Capital LP acquired a new stake in Lucid Diagnostics in the 2nd quarter valued at $6,420,000. Sunbelt Securities Inc. grew its position in Lucid Diagnostics by 134.4% in the first quarter. Sunbelt Securities Inc. now owns 900,013 shares of the company’s stock valued at $1,035,000 after acquiring an additional 516,014 shares during the period. Finally, XML Financial LLC grew its position in Lucid Diagnostics by 44.8% in the second quarter. XML Financial LLC now owns 323,195 shares of the company’s stock valued at $346,000 after acquiring an additional 100,000 shares during the period. 74.01% of the stock is currently owned by institutional investors.

Lucid Diagnostics Trading Up 0.7%

Shares of NASDAQ LUCD opened at $0.41 on Wednesday. The firm has a market capitalization of $83.13 million, a price-to-earnings ratio of -0.87 and a beta of 1.19. Lucid Diagnostics has a one year low of $0.30 and a one year high of $1.63. The business has a fifty day simple moving average of $0.69 and a 200 day simple moving average of $1.02.

Lucid Diagnostics (NASDAQ:LUCD) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.06). The business had revenue of $1.47 million for the quarter, compared to analyst estimates of $1.43 million. On average, research analysts anticipate that Lucid Diagnostics will post -0.23 earnings per share for the current fiscal year.

About Lucid Diagnostics

Lucid Diagnostics Inc (NASDAQ: LUCD) is a medical diagnostics company focused on improving the detection of esophageal disease. The company develops and commercializes diagnostic technologies intended to identify patients at elevated risk of esophageal cancer, particularly those with gastroesophageal reflux disease (GERD).

Lucid’s principal products include EsoGuard, a laboratory-developed DNA test that analyzes cells collected from the esophagus for molecular changes associated with Barrett’s esophagus and esophageal cancer risk, and EsoCheck, a swallowable, balloon-based device designed to collect cells from the esophageal lining.